Shares of Asian pharmaceutical companies fell after US President Donald Trump said he planned to order a cut in US ...

Shares of Asia drugmakers fell on Monday after President Trump said he would sign an executive order aimed at lowering the cost of prescription drugs.

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

TOKYO, - Japan's Nikkei share average rose on Monday as indications of progress in U.S.-China trade talks boosted hopes of a deal between the major economies. As of 0202 GMT, the Nikkei was up 0.2% at ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...

The famous trees, and the festival associated with their blossoming each spring, is part of a tradition for the global ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Daiichi Sankyo reaffirms US manufacturing expansion, including for Enhertu, will help with Trump's proposed tariffs. Ohio ...